Eureka 93 Inc., a cannabidiol (CBD) life sciences company, engages in the research, development, extraction, production, processing, and distribution of CBD and other cannabinoids in the United States and Canada.
The last earnings update was 64 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Eureka 93 is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Eureka 93 has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Eureka 93. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Eureka 93's earnings available for a low price, and how does
this compare to other companies in the same industry?
Eureka 93 has negative assets, we can't compare the value of its assets to the CA Personal Products industry average.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Eureka 93's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eureka 93 has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Eureka 93's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Eureka 93's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Eureka 93's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Eureka 93 is high growth as no earnings estimate data is available.
Unable to determine if Eureka 93 is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Eureka 93's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. David Rendimonti serves as CEO of LiveWell Foods Canada Inc. since October 5, 2018, also President at LiveWell Foods Canada Inc. He has been a Director of Eureka 93 Inc. since July 17, 2019. He serves as Chief Executive Officer of LiveWell Canada Inc. also known as Eureka 93 Inc. He is a healthcare leader with a 30-year track record of building and leading No. 1 brands, including senior roles at some of the world's most prominent organizations such as Johnson & Johnson, Pfizer, Wyeth Pharmaceuticals and Merck. Mr. Rendimonti drove innovation within the Biotech and Women's Health markets in Canada and has extensive experience in global health and wellness markets. His pioneering spirit, pursuit of innovation and background in capital markets makes him ideally suited to optimize the Company's growth trajectory in the fast-developing cannabis and hemp-based health and wellness markets worldwide.
Insufficient data for David to compare compensation growth.
Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
CEO & Director
President & Chief Operating Officer
Chief Financial Officer
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Eureka 93 board of directors is less than 3 years, this suggests a new board.
Board of Directors
CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Eureka 93 Inc., a cannabidiol (CBD) life sciences company, engages in the research, development, extraction, production, processing, and distribution of CBD and other cannabinoids in the United States and Canada. The company offers hemp-derived CBD products, full plant extracts, and isolate powder. It is also involved in the development and manufacture of natural health products, as well as nutraceutical contract manufacturing business. The company is headquartered in Gatineau, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.